Initially there was no specific way to reverse the anticoagulant effect of dabigatran in the the the the the the the the the the the event you know so like so like so well okay like you know of a a a a a a a a a a a major bleeding event, unlike for warfarin, but a dabigatran antidote (idarucizumab) was approved by the FDA in 2015.